|
PL193464B1
(pl)
*
|
1998-07-06 |
2007-02-28 |
Janssen Pharmaceutica Nv |
Zastosowanie inhibitora białkowej transferazy farnezylowej
|
|
EA200100766A1
(ru)
*
|
1999-02-11 |
2002-02-28 |
Пфайзер Продактс Инк. |
Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
|
|
EP1230232B1
(en)
|
1999-11-05 |
2004-02-25 |
Cytovia, Inc. |
Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
ES2212971T3
(es)
*
|
1999-11-30 |
2004-08-16 |
Pfizer Products Inc. |
Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
|
|
HN2000000266A
(es)
*
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
|
AU3653301A
(en)
*
|
2000-01-28 |
2001-08-07 |
Merck & Co., Inc. |
Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
|
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
|
AU2001293826A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
|
JP4974437B2
(ja)
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
|
|
US7196094B2
(en)
|
2000-09-25 |
2007-03-27 |
Janssen Pharmaceutica, N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
|
|
EP1322644A1
(en)
*
|
2000-09-25 |
2003-07-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
|
EE05195B1
(et)
*
|
2000-10-02 |
2009-08-17 |
Janssen Pharmaceutica N.V. |
Kinoliini ja kinolinooni derivaadid glutamaatretseptori antagonistidena, nende saamine ja kasutamine ravimite valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
|
|
JP4348080B2
(ja)
|
2000-11-21 |
2009-10-21 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害するベンゾ複素環誘導体
|
|
ES2260316T3
(es)
|
2000-12-27 |
2006-11-01 |
Janssen Pharmaceutica N.V. |
Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
|
|
PT1351954E
(pt)
*
|
2000-12-27 |
2006-09-29 |
Janssen Pharmaceutica Nv |
Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
|
|
US6858607B1
(en)
|
2001-05-16 |
2005-02-22 |
Cytovia, Inc. |
7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
CA2447010C
(en)
*
|
2001-05-16 |
2011-08-02 |
Cytovia, Inc. |
Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
WO2002092076A1
(en)
*
|
2001-05-16 |
2002-11-21 |
Cytovia, Inc. |
Substituted coumarins and quinolines as caspases activators
|
|
US20030139332A1
(en)
*
|
2001-07-09 |
2003-07-24 |
The Regents Of The University Of California |
Use of matrix metalloproteinase inhibitors to mitigate nerve damage
|
|
CA2469275C
(en)
|
2001-12-19 |
2011-09-06 |
Janssen Pharmaceutica N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
|
AU2003223970B2
(en)
*
|
2002-03-22 |
2008-03-06 |
Janssen Pharmaceutica N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
|
AU2003226737B2
(en)
*
|
2002-03-29 |
2008-09-04 |
Janssen Pharmaceutica N.V. |
Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
|
|
EP1497295B1
(en)
|
2002-04-15 |
2006-08-16 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
|
|
WO2003096982A2
(en)
|
2002-05-16 |
2003-11-27 |
Cytovia, Inc. |
Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
CA2484702A1
(en)
|
2002-05-16 |
2003-11-27 |
Cytovia, Inc. |
Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
|
CA2510850A1
(en)
*
|
2002-12-19 |
2004-07-08 |
Pfizer Inc. |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
|
|
JP4695588B2
(ja)
|
2003-02-26 |
2011-06-08 |
スージェン， インク． |
プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物
|
|
TW200504057A
(en)
*
|
2003-02-27 |
2005-02-01 |
Chugai Pharmaceutical Co Ltd |
Benzothiophene derivative
|
|
NZ544697A
(en)
*
|
2003-07-22 |
2009-03-31 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as inhibitors of c-fms kinase
|
|
US7517890B2
(en)
|
2003-11-20 |
2009-04-14 |
Children's Hospital Medical Center |
GTPase inhibitors and methods of use
|
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
WO2005089496A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
ME01788B
(me)
*
|
2004-08-26 |
2011-02-28 |
Pfizer |
Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
|
|
CA2578075A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
|
GEP20094845B
(en)
*
|
2004-08-26 |
2009-11-25 |
Pfizer |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
|
|
WO2006041900A2
(en)
*
|
2004-10-07 |
2006-04-20 |
Cytovia, Inc. |
SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
|
|
EP1920048A4
(en)
|
2005-07-29 |
2009-12-09 |
Childrens Hosp Medical Center |
GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
|
|
EP1933871B1
(en)
|
2005-09-07 |
2013-04-24 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
CA2623125A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2545919A1
(en)
|
2005-12-23 |
2013-01-16 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
RS20080525A
(sr)
|
2006-05-09 |
2009-09-08 |
Pfizer Products Inc., |
Derivati cikloalkilamino kiseline i njihove farmaceutske kompozicije
|
|
MY150756A
(en)
|
2006-08-21 |
2014-02-28 |
Hoffmann La Roche |
Tumor theraphy with an anti-vegf antibody
|
|
EP2162450B1
(en)
*
|
2007-05-23 |
2015-02-25 |
Allergan, Inc. |
((bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
|
|
SI2155733T1
(sl)
*
|
2007-05-23 |
2012-12-31 |
Allergan, Inc |
Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka
|
|
US8129356B2
(en)
*
|
2007-10-01 |
2012-03-06 |
Vanderbilt University |
Bmx mediated signal transduction in irradiated vascular endothelium
|
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
|
JP2012508768A
(ja)
*
|
2008-11-13 |
2012-04-12 |
リンク・メディスン・コーポレーション |
アザキノリノン誘導体及びその使用
|
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US20100204221A1
(en)
*
|
2009-02-09 |
2010-08-12 |
Hariprasad Vankayalapati |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2542893A2
(en)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
|
HK1213250A1
(zh)
|
2012-10-16 |
2016-06-30 |
Janssen Pharmaceutica, N.V. |
RORγT的雜芳基連接的喹啉基調節劑
|
|
MY189505A
(en)
|
2012-10-16 |
2022-02-16 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of roryt
|
|
PE20151203A1
(es)
|
2012-10-16 |
2015-08-31 |
Janssen Pharmaceutica Nv |
MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
CA2905993C
(en)
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
AU2014334619A1
(en)
|
2013-10-15 |
2016-04-21 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORyt
|
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
CA2927182A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
Quinolinyl modulators of ror.gamma.t
|
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
|
JP6877429B2
(ja)
|
2015-12-03 |
2021-05-26 |
アジオス ファーマシューティカルズ， インコーポレイテッド |
Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
|
|
CN108003150A
(zh)
*
|
2016-10-31 |
2018-05-08 |
河南工业大学 |
4-杂芳基喹啉酮衍生物的制备方法及其应用
|
|
JP2021530554A
(ja)
|
2018-07-26 |
2021-11-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤
|
|
EP3924351B1
(en)
|
2019-02-12 |
2025-05-21 |
Sumitomo Pharma America, Inc. |
Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol
|
|
EP4013402B1
(en)
|
2019-08-16 |
2024-11-06 |
Children's Hospital Medical Center |
Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|